open-label BE trials maintain blindness [Study Per­for­mance]

posted by dshah  – India/United Kingdom, 2023-10-17 11:25 (54 d 23:46 ago) – Posting: # 23760
Views: 923

Hi kimhuang!

❝ Per protocol, bioanalytical staff is blinded,others is not mentioned in protocol, but study team discuss PK parameters (without treatment assignment,such as Pre-dose concentration, abnormal PK concentration profiles, λz estimation, %AUCextrap etc.) to decide analysis set in data review meeting before database lock.


So there are no SOP w.r.t. pre-dose concentration, abnormal PK concentration, λz estimation? Generally QA goes ahead with protocol inclusion/exclusion criteria and SOP of BA.

❝ ❝ 3. Who has access to the rand. code? I do not mean who should have access.

❝ As it's an open-label BE study, CRF collect treatment sequence, so study team can access to the treatment assigment.


Does BA team also have access to CRF? Then how it is blinded?

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
22,823 posts in 4,786 threads, 1,633 registered users;
34 visitors (0 registered, 34 guests [including 7 identified bots]).
Forum time: 10:11 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5